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Signs	and	Symptoms
Malignant	hyperthermia	occurs	in	
patients	who	have	a	genetic	defect	in	their	
ryanodine	receptor	subtype	1	(RYR1),	
which	is	a	large	ion	channel	that	facilitates	
the	release	of	calcium	from	the	
sarcoplasmic	reticulum	(SR)	in	skeletal	
muscle	(Schneiderbanger	et	al.,	2014).	
Calcium	is	released	from	the	SR	during	
muscle	contraction	and	normally	
undergoes	reuptake	after	muscle	
contraction	has	been	completed.	During	
an	MH	crisis,	when	susceptible	patients	
are	exposed	to	triggering	agents	(volatile	
anesthetics	and	succinylcholine),	there	is	a	
prolonged	opening	of	the	RYR1	receptor	
channels,	which	results	in	an	uncontrolled	
release	of	calcium	and	unrelenting	muscle	
activation	which	presents	as	rigidity	
(Schneiderbanger	et	al.,	2014).	This	
sustained	muscle	contraction	causes	
increased	sympathetic	activity	such	as	
tachycardia	and	hypertension,	increased	
oxygen	consumption,	production	of	carbon	
dioxide,	and	high	body	temperature	
(Schneiderbanger	et	al.,	2014).	Cellular	
adenosine	triphosphate	stores	are	
depleted,	and	aerobic	metabolism	is	
eventually	useless	and	anaerobic	
metabolism	begins.	This	produces	lactic	
acid	and	ultimately	causes	cell	death	and	
destruction	(Riazi	et	al.,	2014).		This	
breakdown	of	cellular	membrane	integrity	
leads	to	the	release	of	potassium,	
myoglobin,	and	creatine	phosphokinase	
into	the	bloodstream	(Nagelhout	and	
Plaus,	2014).	The	release	of	these	contents	
into	circulation	can	further	cause	
rhabdomyolysis,	cardiac	arrhythmias,	
pulmonary	edema,	and	disseminated	
intravascular	coagulation	(DIC)	(Riazi	et	al.,	
2014).	
Malignant	hyperthermia	causes	significant	and	potentially	lethal	distress	to	the	
body	if	not	properly	recognized	and	treated.	But	it’s	important	to	realize	that	since	
this	condition	is	genetically	linked,	it	can	be	avoided.	Because	of	its	significance,	
malignant	hyperthermia	should	be	a	priority	during	an	anesthesia	provider’s	
preoperative	assessment.	Patient’s	should	be	asked	if	they	or	their	family	members	
have	ever	experienced	any	complications	related	to	anesthesia,	specifically	regarding	
a	high	fever	or	muscle	rigidity.	This	simple	assessment	can	avoid	the	risks	associated	
with	volatile	anesthetics	and	depolarizing	neuromuscular	blockers,	and	prevent	the	
patient	from	experiencing	deadly	symptoms	such	as	ventricular	fibrillation,	
rhabdomyolysis	and	renal	failure,	pulmonary	edema,	DIC,	etc.	This	condition	shares	
many	of	the	same	signs	and	symptoms	of	other	pathological	disorders.	It	becomes	
even	more	important	to	be	diligent	with	assessment	skills	and	understand	the	
pathology	to	comprehend	how	this	might	happen	and	cause	a	lethal	condition.	
Because	it	is	such	a	pathologically	serious	disorder,	increased	education	for	patients,	
their	families,	and	providers	are	necessary	and	important	to	provide	safe	anesthetic	
care.	
Malignant	hyperthermia	(MH)	is	a	
serious,	life-threatening	emergency	that	
any	diligent	certified	registered	nurse	
anesthetist	(CRNA)	needs	to	be	aware	
of.	Along	with	a	myriad	of	conditions	
and	potential	complications	that	can	
occur	during	anesthesia,	MH	stands	out	
as	one	that	requires	prevention,	prompt	
recognition,	and	treatment	to	avoid	
rapid	deterioration	of	the	patient’s	
condition.	
Malignant	hyperthermia	is	known	as	
a	pharmacogenetic	disorder	which	
manifests	itself	in	the	skeletal	muscle	
(Heytens,	Forget,	Scholtès,	&	
Veyckemans,	2015).	When	a	susceptible	
patient,	who	carries	the	autosomal	
dominant	trait,	is	exposed	to	volatile	
anesthetics	and/or	the	neuromuscular	
blocker	succinylcholine,	a	detrimental	
response	can	occur.	This	response	is	a	
hypermetabolic	state	with	hypercapnia,	
hemodynamic	instability,	rigidity,	
hyperthermia,	and	signs	of	
rhabdomyolysis	(Heytens	et	al.,	2015).	
This	response	is	due	to	the	calcium	
release	from	the	sarcoplasmic	reticulum	
into	the	cytosol	(MacKay,	Wilkerson,	
Kraeva,	Rosenberg,	&	Kennedy,	2016).	
MH	is	a	rare	condition	with	incidences	
between	1/5,000	and	1/50,000	
(Nagelhout	and	Plaus,	2014,	p.	829),	and	
often	occurs	during	the	induction	of	
anesthesia	but	can	also	occur	
intraoperatively	or	one	hour	post	
operatively	(Cain,	Riess,	Gettrust,	&	
Novalija,	2014).	Because	MH	can	
manifest	itself	at	several	different	
periods	during	the	perioperative	phase,	
CRNA’s	must	be	conscientious	health	
care	providers.		Incidences	occur	in	
patients	who	carry	the	mutated	
autosomal	dominant	type-1	ryanodine	
receptor	(RYR1)	gene	(Riazi	et	al.,	2014).		
If	these	patients	who	carry	the	mutated	
gene	are	exposed	to	triggering	agents,	
and	MH	is	not	properly	recognized	and	
treated,	the	result	could	be	irreversible	
damage	and	potential	death	due	to	the	
sustained	hypermetabolic	state	the	
body	endures.	It	is	worth	exploring	the	
pathophysiology,	signs,	symptoms,	and	
treatment	to	prevent	this	condition	
from	happening.	
• Early	clinical	signs	of	MH	include	
increasing	heart	rate	and	end	tidal	
carbon	dioxide	(Stratman,	Flynn,	&	
Hatton,	2009)
• Hyperthermia,	with	temperature	
rising	as	quickly	as	1	degree	Celsius	
every	5	minutes	(Stratman,	Flynn,	&	
Hatton,	2009)
• Muscle	rigidity,	especially	in	the	jaw,	
chest,	and	extremities	(Stratman,	
Flynn,	&	Hatton,	2009)
• Later	signs	include	acidosis,	
cyanosis,	and	various	electrolyte	
imbalances	that	can	also	manifest	as	
cardiac	arrhythmias	(Stratman,	
Flynn,	&	Hatton,	2009)
• Rhabdomyolysis	with	
myoglobinemia,	myoglobinuria,	
hyperkalemia	and	acute	renal	
failure	(Stratman,	Flynn,	&	Hatton,	
2009)
• Any	of	the	above	listed	signs	and	
symptoms	can	quickly	turn	into	
cardiac	arrest	(Stratman,	Flynn,	&	
Hatton,	2009)
• Refer	to	Table	1	for	detailed	early	
and	late	signs	and	symptoms
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Table	1
Although	malignant	hyperthermia	is	a	rare	medical	emergency,	it	is	vital	that	
clinicians	and	patients	are	prepared	and	educated	for	the	surgical	procedure	and	the	
risk	for	complications	with	a	detailed	plan	in	place	(Johns,	Stoudt,	Scholtis,	&	Gavel,	
2012).	Malignant	hyperthermia	requires	immediate	recognition	and	treatment	to	
increase	the	patient’s	chance	of	survival.	Providers	need	to	know	its	triggers	(volatile	
anesthetics	and	succinylcholine),	and	a	thorough	pre-operative	assessment	must	be	
completed	to	identify	any	history	or	risk	factors	for	MH.	It	is	important	that	all	OR	
staff	regularly	review	the	standards	and	procedure	for	dealing	with	an	MH	crisis,	as	it	
is	a	rare	occurrence.	The	whole	operating	room	must	work	as	a	team	and	be	familiar	
with	signs	and	symptoms	of	MH	and	understand	the	protocol	in	order	to	properly	
react	and	treat	the	patient	for	the	best	possible	outcome.	
Conclusion
As	mentioned	previously,	the	goal	should	be	to	avoid	triggering	agents	in	the	presence	of	
someone	who	has	a	history	of	MH	or	has	a	family	member	with	a	history	of	MH.	There	
are	often	special	OR’s	with	specific	equipment	that	can	be	used	in	these	circumstances.	
However,	the	RYR1	defect	may	not	be	known	and	a	MH	crisis	may	occur	in	the	middle	of	
surgery.	MH	should	be	promptly	recognized	and	many	things	needs	to	happen	at	the	
same	time.	
• All	triggering	agents	should	be	discontinued,	an	increase	in	oxygenation	to	100%	
FiO2	should	be	completed,	and	the	patient	should	be	given	non-triggering	relaxants	
and	anesthetics	such	as	propofol	and/or	midazolam	(MHAUS,	2015)
• Dantrolene	should	be	administered.	Dantrolene	is	a	specific	ryanodine	receptor	
antagonist	that	prevents	calcium	from	being	released	and	prevent	the	muscle	cells	
from	contracting	(Seifert,	Wahr,	Pace,	Cochrane,	&	Bagnola,	2014).	The	dose	of	
dantrolene	is	2.5	mg/kg	every	5	minutes	repeatedly	until	a	maximum	dose	of	30	
mg/kg	has	been	reached.	This	medication	should	be	rapidly	infused	through	a	large	
bore	IV	(Seifert	et	al.,	2014)	
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• The	patient	should	also	be	cooled	with	ice	packs,	cold	wraps,	and/or	chilled	IV	
normal	saline	with	an	attempt	to	keep	their	temperature	less	then	39	degrees	
Celsius	(Dirksen,	Van	Wicklin,	Mashman,	Neiderer,	&	Merritt,	2013)
• Metabolic	acidosis	and	hyperkalemia	may	be	treated	with	sodium	bicarbonate,	
hyperventilation,	glucose	and	insulin	and	arterial	blood	gases,	electrolytes,	and	
blood	levels	should	be	checked	every	15	minutes	(Dirksen	et	al.,	2013)	
• It	should	also	be	a	goal	to	maintain	the	patient’s	urine	output	greater	than	2	
ml/kg/hr	with	adequate	hydration,	furosemide,	and	mannitol	as	needed	(Nagelhout	
and	Plaus,	2014,	p.	829).	
• While	everything	else	is	going	on,	an	OR	team	member	should	also	call	the	MH	
hotline	at	1-800-644-9737	and	be	prepared	to	give	name,	number,	facility	and	email	
(MHAUS,	2015)
Implications	for	Nursing	Care
Early	Signs	and	Symptoms Late	Signs	and	Symptoms
Increased	ETCO2 Cyanosis
Muscle	Rigidity Pyrexia
Cardiac	abnormalities Disseminated	intravascular	
coagulation
Generalized	erythematous	flush Left	ventricular	failure
Electrolyte	imbalance Metabolic	acidosis
(Stratman,	Flynn,	&	Hatton,	2009)
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